Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ADG20 for the Prevention of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tests negative for current or previous SARS-CoV-2 infection by RT-PCR and serology (Pre-exposure population only)~* Is at high risk of SARS-CoV-2 infection as assessed by the Investigator:~  1. Post-exposure population: exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case). Note: Participants with recent exposure to a laboratory-confirmed index case must be asymptomatic and randomized within 5 days (120 hours) of collection of the index case's positive SARS-CoV-2 diagnostic test.~ 2. Pre-exposure population: Occupational, housing, recreational and/or social conditions that are likely to increase risk of exposure to SARS-CoV-2.~* Agrees to defer receipt of COVID-19 vaccination for minimum of 180 days (6 months) after dosing~Exclusion Criteria:~* Has received (1) a SARS-CoV-2 vaccine, (2) mAb or (3) convalescent plasma from a person who has recovered from COVID-19 or prior participation in SARS-CoV2 vaccine, convalescent plasma, or mAb clinical trial any time prior to participation in the study.~* Receipt of any investigational product within 30 days or 5 half lives before the day of enrollment.~* Is acutely ill or febrile 72 hours before or at Screening or has other COVID-19 symptoms including cough, fatigue, muscle or body aches, headache, or loss of taste or smell. Fever is defined as a body temperature ≥38.0°C (≥100.4°F).~* Has received or plans to receive a non-COVID-19 vaccine within 28 days before or after dosing (except for seasonal influenza vaccine, which is not permitted within 14 days before or after dosing).~NOTE: Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADG20 (Type: EXPERIMENTAL): Participants will be dosed on Day 1 with ADG20 IM
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be dosed on Day 1 with placebo IM

Based on this trial design, predict the completion outcome and termination type (if applicable).